Table 1 Patient and treatment demographics (n = 213)
From: Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results
Patients, n = 213 | Risk groupa | ||
|---|---|---|---|
Low n = 47 | Intermediate n = 56 | High n = 110 | |
Age y | |||
median | 68 | 69 | 71 |
range | 52–81 | 47–86 | 54–86 |
cT-stage n (%) | |||
T1c-2a | 47 (100) | 46 (82.1) | 22 (20.0) |
T2b | – | 9 (16.1) | 2 (1.8) |
T2c-4 | – | – | 86 (78.2) |
NA | – | 1 (1.8) | – |
iPSA ng/ml n (%) | |||
< 10 | 47 (100) | 22 (39.3) | 39 (35.4) |
10–20 | – | 34 (60.7) | 41 (37.3) |
> 20 | – | - | 30 (27.3) |
median | 7.5 | 11.1 | 11.8 |
range | 1.9–10.0 | 1.3–19.0 | 2.52–300.0 |
Gleason score n (%) | |||
≤ 6 | 47 (100) | 27 (48.2) | 33 (30.0) |
7 | – | 29 (51.8) | 50 (45.5) |
≥ 8 | – | – | 27 (24.5) |
ADT n (%) | |||
yes | 13 (27.7) | 27 (48.2) | 97 (88.2) |
ADT duration n (%) | |||
7 mo or less | 12 (25.5) | 17 (30.4) | 28 (25.5) |
12–18 mo | – | 2 (3.6) | 13 (11.8) |
24 mo or longer | – | 7 (12.5) | 46 (41.8) |
NA | 1 (2.1) | 1 (1.8) | 10 (9.1) |
Irradiation dose n (%) | |||
35 Gy | 3 (6.4) | 10 (17.9) | 22 (20.0) |
36.25 Gy | 44 (93.6) | 46 (82.1) | 88 (80.0) |